Rofecoxib is a selective COX-2 inhibitor with anti-inflammatory, analgesic, and antipyretic properties. Its role in suppressing prostaglandin synthesis has made it a tool for studying COX-2 overexpression in cancer models, particularly in research related to tumor angiogenesis and cell proliferation.